Argenx stock hits a 52-week high after a deal close
Published on 08/28/2026 at 08:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
argenx SE (NL0010832176) stock touched a new 52-week high on August 27, 2026, with shares trading near $1,058 after the company closed its Forte Biosciences acquisition. The same session also left the stock at a market value of $66.20 billion and a volume of 117,743 shares.
Acquisition closes
Per the completed acquisition report, argenx finished the purchase of Forte Biosciences on August 27, 2026 and paid $77.00 per share in cash. The deal added FB102, a first-in-class anti-CD122 antibody, to the pipeline and converted Forte into a wholly owned subsidiary.
That keeps the transaction immediate and measurable for investors: 19,894,879 Forte shares were tendered, and the acceptance level reached 87.13% of Forte's outstanding common stock. The same filing-style report says Forte stock will no longer trade on Nasdaq after the merger.
Quarterly numbers
MarketBeat's August 27, 2026 coverage said argenx reported quarterly EPS of $7.32 on revenue of $1.54 billion, versus consensus expectations of $5.86 and $1.45 billion. That means EPS beat estimates by $1.46, while revenue came in $90 million above the consensus figure.
The same report put the consensus analyst rating at Moderate Buy with a $1,157.50 price target, while Wells Fargo lifted its target to $1,415 and UBS upgraded the stock to buy. A few days of analyst revisions can matter because the market has already pushed argenx to a fresh 52-week high.
Why FB102 matters
FB102 is now the most concrete new asset in the portfolio, and the company describes it as a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease. The addition broadens the immunology pipeline beyond efgartigimod and gives management another program with later-stage optionality.
For investors, the mix is simple: a $77.00 acquisition price, a $1.54 billion quarterly revenue base, and a stock that traded as high as $1,061.13 on August 27, 2026. The next read-through will be whether the new asset changes the growth profile more than the deal price changes the balance sheet.
Vyvgart remains central
Vyvgart remains argenx's flagship product and the commercial engine behind the quarter's scale. The company still frames its broader immunology strategy around FcRn biology and the expansion of antibody-based medicines across severe autoimmune diseases.
Price and trading
As of August 27, 2026, argenx last traded at $1,058.30, after ranging as high as $1,061.13 during the session. The stock's 200-day moving average was $831.06, which leaves the latest price well above the longer-term trend line.
Fact box
Company: argenx SE
ISIN: NL0010832176
Ticker: ARGX
Exchange: Nasdaq
Price (as of August 27, 2026, 4:00 p.m. ET): $1,058.30 USD
Market cap: $66.20 billion (as of August 27, 2026)
Sector / Industry: Health Care / Biotechnology
Index membership: Nasdaq-100
Next earnings date: October 22, 2026
